On February 23, 2023, Fortunefeatured insights from AFAR Scientific Director Nir Barzilai, MD, and AFAR Board Member David Sinclair, PhD, on how biological age can be targeted through interventions such as metformin. The article also highlights the potential impact of the AFAR-managed TAME Trial.
In addition to serving as AFAR’s Scientific Director, Dr. Barzilai is a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award of Distinction recipient, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Dr. Sinclair is an AFAR Board Member, a 2000 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2018 Irving S. Wright Award recipient. He is also a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School.
Read the article, “Is Reverse Aging Already Possible? Drugs That Could Treat Aging Might Already Be On The Pharmacy Shelves,” here.
